CVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx (NASDAQ: CVRX) announced that its management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026, at 10:40 a.m. CT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CVRx (NASDAQ: CVRX) announced that its management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026, at 10:40 a.m. CT. A live webcast and limited-time archived replay will be available at ir.cvrx.com.
Details
News Market Reaction – CVRX
On May 21, the first trading day after this news, CVRX closed 0.17% above the previous close.
Data tracked by StockTitan Argus for the May 21 session.
Key Figures
- Conference edition
- 46th Annual
- William Blair Growth Stock Conference
- Presentation date
- June 2, 2026
- Scheduled conference presentation in Chicago
- Presentation time
- 10:40 a.m. CT
- Start time of company presentation
Historical Context
-
Humana Medicare Advantage coverage policy for Barostim therapy announced.
-
Q1 2026 revenue growth and margin expansion with maintained guidance.
-
First patient enrolled in large BENEFIT-HF heart failure trial for Barostim.
-
Announcement of date and time for Q1 2026 results and webcast.
-
Nomination of Michael Dale to board, emphasizing Barostim commercial expertise.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
neuromodulation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The Company's presentation will begin at 10:40 a.m. (CT).
A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.
Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.